The rapidly advancing field of biodefense benefits many other, critical public health concerns.
Identifieur interne : 002420 ( PubMed/Checkpoint ); précédent : 002419; suivant : 002421The rapidly advancing field of biodefense benefits many other, critical public health concerns.
Auteurs : James C. Burnett [États-Unis] ; Rekha G. Panchal ; M Javad Aman ; Sina BavariSource :
- Discovery medicine [ 1944-7930 ] ; 2005.
Abstract
Extract: In 2001, the public was introduced to one of the deadliest of biowarfare agents -- Bacillus anthracis -- the bacterium that causes anthrax. At the time, it was unimaginable that one might come into contact with such a deadly pathogen by simply opening the mail. Today anthrax is a nearly ubiquitous household word. This single act of bioterrorism had a profound effect in that it clearly demonstrated that even a small-scale attack could incur huge repercussions: the loss of life, the need for thousands to be treated with prophylaxis, public panic, and a large economic toll. Following this realization, a major government effort to find new and more effective ways to detect, diagnose, and therapeutically counter biothreat agents was initiated. So, how has this initiative fared?
PubMed: 20704875
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:20704875Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The rapidly advancing field of biodefense benefits many other, critical public health concerns.</title>
<author><name sortKey="Burnett, James C" sort="Burnett, James C" uniqKey="Burnett J" first="James C" last="Burnett">James C. Burnett</name>
<affiliation wicri:level="2"><nlm:affiliation>Target Structure-Based Drug Discovery Group, Developmental Therapeutics Program, National Cancer Institute, Frederick, MD 21702, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Target Structure-Based Drug Discovery Group, Developmental Therapeutics Program, National Cancer Institute, Frederick, MD 21702</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Panchal, Rekha G" sort="Panchal, Rekha G" uniqKey="Panchal R" first="Rekha G" last="Panchal">Rekha G. Panchal</name>
</author>
<author><name sortKey="Aman, M Javad" sort="Aman, M Javad" uniqKey="Aman M" first="M Javad" last="Aman">M Javad Aman</name>
</author>
<author><name sortKey="Bavari, Sina" sort="Bavari, Sina" uniqKey="Bavari S" first="Sina" last="Bavari">Sina Bavari</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2005">2005</date>
<idno type="RBID">pubmed:20704875</idno>
<idno type="pmid">20704875</idno>
<idno type="wicri:Area/PubMed/Corpus">002614</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002614</idno>
<idno type="wicri:Area/PubMed/Curation">002614</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002614</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002420</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002420</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">The rapidly advancing field of biodefense benefits many other, critical public health concerns.</title>
<author><name sortKey="Burnett, James C" sort="Burnett, James C" uniqKey="Burnett J" first="James C" last="Burnett">James C. Burnett</name>
<affiliation wicri:level="2"><nlm:affiliation>Target Structure-Based Drug Discovery Group, Developmental Therapeutics Program, National Cancer Institute, Frederick, MD 21702, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Target Structure-Based Drug Discovery Group, Developmental Therapeutics Program, National Cancer Institute, Frederick, MD 21702</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Panchal, Rekha G" sort="Panchal, Rekha G" uniqKey="Panchal R" first="Rekha G" last="Panchal">Rekha G. Panchal</name>
</author>
<author><name sortKey="Aman, M Javad" sort="Aman, M Javad" uniqKey="Aman M" first="M Javad" last="Aman">M Javad Aman</name>
</author>
<author><name sortKey="Bavari, Sina" sort="Bavari, Sina" uniqKey="Bavari S" first="Sina" last="Bavari">Sina Bavari</name>
</author>
</analytic>
<series><title level="j">Discovery medicine</title>
<idno type="eISSN">1944-7930</idno>
<imprint><date when="2005" type="published">2005</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Extract: In 2001, the public was introduced to one of the deadliest of biowarfare agents -- Bacillus anthracis -- the bacterium that causes anthrax. At the time, it was unimaginable that one might come into contact with such a deadly pathogen by simply opening the mail. Today anthrax is a nearly ubiquitous household word. This single act of bioterrorism had a profound effect in that it clearly demonstrated that even a small-scale attack could incur huge repercussions: the loss of life, the need for thousands to be treated with prophylaxis, public panic, and a large economic toll. Following this realization, a major government effort to find new and more effective ways to detect, diagnose, and therapeutically counter biothreat agents was initiated. So, how has this initiative fared?</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">20704875</PMID>
<DateCompleted><Year>2012</Year>
<Month>10</Month>
<Day>02</Day>
</DateCompleted>
<DateRevised><Year>2014</Year>
<Month>07</Month>
<Day>30</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1944-7930</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>5</Volume>
<Issue>28</Issue>
<PubDate><Year>2005</Year>
<Month>Aug</Month>
</PubDate>
</JournalIssue>
<Title>Discovery medicine</Title>
<ISOAbbreviation>Discov Med</ISOAbbreviation>
</Journal>
<ArticleTitle>The rapidly advancing field of biodefense benefits many other, critical public health concerns.</ArticleTitle>
<Pagination><MedlinePgn>371-7</MedlinePgn>
</Pagination>
<Abstract><AbstractText Label="UNLABELLED">Extract: In 2001, the public was introduced to one of the deadliest of biowarfare agents -- Bacillus anthracis -- the bacterium that causes anthrax. At the time, it was unimaginable that one might come into contact with such a deadly pathogen by simply opening the mail. Today anthrax is a nearly ubiquitous household word. This single act of bioterrorism had a profound effect in that it clearly demonstrated that even a small-scale attack could incur huge repercussions: the loss of life, the need for thousands to be treated with prophylaxis, public panic, and a large economic toll. Following this realization, a major government effort to find new and more effective ways to detect, diagnose, and therapeutically counter biothreat agents was initiated. So, how has this initiative fared?</AbstractText>
<AbstractText Label="ANSWER" NlmCategory="CONCLUSIONS">in a very short period of time the scientific community has responded with a massive and productive effort. Driving the research advances described in this review: 1) a vastly improved understanding of the biological mechanisms and machinery used by biothreat agents; 2) state-of-the-art high-throughput screening technologies; and 3) more efficient, standardized methods and improved protocols for detecting, identifying, and diagnosing biowarfare agents. Furthermore, as with all good science, many recent biodefense research discoveries/advances have also directly facilitated our understanding and ability to treat other diseases, including antibiotic resistant bacteria and viruses (such as HIV and SARS).</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Burnett</LastName>
<ForeName>James C</ForeName>
<Initials>JC</Initials>
<AffiliationInfo><Affiliation>Target Structure-Based Drug Discovery Group, Developmental Therapeutics Program, National Cancer Institute, Frederick, MD 21702, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Panchal</LastName>
<ForeName>Rekha G</ForeName>
<Initials>RG</Initials>
</Author>
<Author ValidYN="Y"><LastName>Aman</LastName>
<ForeName>M Javad</ForeName>
<Initials>MJ</Initials>
</Author>
<Author ValidYN="Y"><LastName>Bavari</LastName>
<ForeName>Sina</ForeName>
<Initials>S</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Discov Med</MedlineTA>
<NlmUniqueID>101250006</NlmUniqueID>
<ISSNLinking>1539-6509</ISSNLinking>
</MedlineJournalInfo>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year>
<Month>8</Month>
<Day>14</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2005</Year>
<Month>8</Month>
<Day>1</Day>
<Hour>0</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2005</Year>
<Month>8</Month>
<Day>1</Day>
<Hour>0</Hour>
<Minute>1</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">20704875</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Maryland</li>
</region>
</list>
<tree><noCountry><name sortKey="Aman, M Javad" sort="Aman, M Javad" uniqKey="Aman M" first="M Javad" last="Aman">M Javad Aman</name>
<name sortKey="Bavari, Sina" sort="Bavari, Sina" uniqKey="Bavari S" first="Sina" last="Bavari">Sina Bavari</name>
<name sortKey="Panchal, Rekha G" sort="Panchal, Rekha G" uniqKey="Panchal R" first="Rekha G" last="Panchal">Rekha G. Panchal</name>
</noCountry>
<country name="États-Unis"><region name="Maryland"><name sortKey="Burnett, James C" sort="Burnett, James C" uniqKey="Burnett J" first="James C" last="Burnett">James C. Burnett</name>
</region>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002420 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 002420 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= SrasV1 |flux= PubMed |étape= Checkpoint |type= RBID |clé= pubmed:20704875 |texte= The rapidly advancing field of biodefense benefits many other, critical public health concerns. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:20704875" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \ | NlmPubMed2Wicri -a SrasV1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |